Bovine Virus Diarrhea (BVD), Herd Health, Udder Health and Reproduction to be Discussed
SUMMIT, NEW JERSEY, July 10, 2014 – Merck Animal Health (known as MSD Animal Health outside the USA and Canada) will present from 19 posters and 1 oral presentation at the 28th World Buiatrics Congress (WBC) in Cairns, Australia, from July 27 – August 1, 2014. WBC brings veterinarians and animal health professionals together to exchange ideas and receive the latest information and insights from international experts on buiatrics. The posters are mainly focused on Bovine Virus Diarrhea (BVD), Herd Health, Lung Health, Udder Health and Reproduction.
“Merck Animal Health’s leadership in the ruminants sector has a solid foundation with a strong commitment to the Science of Healthier Animals™,” said Fernando Heiderich, Merck Animal Health. “We are pleased to have the opportunity to present our data on ruminant health to industry leaders at WBC. We have the right products and the best people to offer a comprehensive set of unique solutions to our customers.”
Abstracts selected for presentations are as follows:
- Inhibition of priming for bovine respiratory syncytial virus specific protective immune responses following parenteral vaccination of passively immune calves
Bovine Virus Diarrhea (BVD):
- The Prevalence and Impact of BVD Congenital Infection in Beef Calves (Poster #84, Session 1)
- Efficacy of an inactivated BVD vaccine against prolonged high infection pressure in a combined vaccination schedule with a live IBR vaccine under field conditions (Poster #183, Session 1)
- Antimicrobial susceptibility of Streptococcus uberis isolated in bovine mastitis in France (Poster #506, Session 2)
- Treatment of mastitis: bactericidal speed of different antibiotics against field strains of Streptococcus uberis (Poster #319, Session 2)
- Comparison of minimum inhibitory concentrations of cephalonium to zone diameters (Poster #467, Session 1)
- Evaluation of the efficacy and performance of preweaned Holstein calves treated with either Resflor Gold or Baytril for bovine respiratory disease (Poster #85, Session 1)
- Identification of risk factors for bovine respiratory disease on Dutch dairy farms (Poster #111, Session 1)
- Prevalence of Bovine Respiratory Disease pathogens in veal calves in the Netherlands (Poster #112, Session 1)
- Prevalence of respiratory pathogen agents in beef cattle on French farms by using the Polymerase Chain Reaction (PCR) method (Poster #504, Session 1)
- Blood levels of immunoglobulins G and total proteins: follow up study on young dairy calves (Poster #320, Session 1)
Lung Health & Welfare:
- Clinical efficacy of a novel Flunixin Transdermal formulation for the control of pyrexia associated with naturally-occurring bovine respiratory disease: a multi-center field trial (Poster #140, Session 2)
- Effectiveness and safety of a novel flunixin meglumine transdermal pour-on solution in the treatment of bovine respiratory disease (Poster #382, Session 2)
- Validation of diagnostic methods for clinical and cytological endometritis in dairy cows (Poster #86, Session 2)
- Resynchronization with unknown pregnancy status using progestin-based timed artificial insemination protocol in beef cattle (Poster #102, Session 2)
- Productivity associated factors in French Charolais cow-calf operations monitored by Bovins Croissance Organization (Poster #505, Session 2)
Other Topics of Interest:
- Effect of Flunixin on Leather Quality of Cattle treated with a Finadyne Transdermal solution (Poster #139, Session 2)
- Comparison of Flunixin Plasma Levels Following A Single Dose Of Flunixin Transdermal Solution To Cattle Allowed Or Prevented From Licking In A Crossover Study (Poster #378, Session 2)
- Post-treatment dosing site assessment following topical administration of a novel formulation of flunixin transdermal solution: summary of seven studies (Poster #380, Session 2)
Selected topics will be featured on the company’s Studio Bovine™, an online channel dedicated to bovine health. Studio Bovine has been designed to meet customers’ need for information in a convenient and engaging format. The channel is an ideal showcase for information and industry leaders at the 28th World Buiatrics Congress.
For more information on the World Buiatrics Congress, please visit www.wbc2014.com.
About Studio Bovine™
An initiative of Merck Animal Health (known as MSD Animal Health outside the USA and Canada), Studio Bovine is dedicated to broadcasting knowledge and farm intelligence in bovine health and productivity. Through online video interviews with leading experts, Studio Bovine is committed to examining complete solutions, equipping veterinarians and farmers with up-to-date and actionable information on issues such as handling, preventive medicine, treatment strategies and performance solutions. Studio Bovine is intended as a platform for interaction and exchange within the global community of bovine professionals. The goal: a shared, integrated vision on Bovine health, sustainability, productivity and quality. For more information and additional video features, please visit www.studiobovine.com.
About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck. Through its commitment to the Science of Healthier Animals™, Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn and Twitter at @MerckAH.
Merck Forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995.
These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2013 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).